 Delcath Systems Inc NASDAQ: DCTH has announced results from the Phase 3 FOCUS study of Hepzato Kit melphalan hydrochloride for injectionhepatic delivery system in patients with liver dominant metastatic ocular melanoma. The FOCUS studys intent-to-treat ITT population included 102 subjects. 